

# The SALSA Study

## Are you taking Semaglutide?

(Ozempic<sup>®</sup>, Wegovy<sup>®</sup>, and Rybelsus<sup>®</sup>)

## We want to hear from you!

All you need is to fill out a survey either online,  
in-person or over the phone.


The survey takes approximately 20 minutes to complete, and  
you will receive a \$30 honorarium for completing the survey.

### YOU MAY BE ELIGIBLE TO TAKE PART IF YOU:

- Are aged 19 years or older.
- Have been prescribed semaglutide for the management of type 2 diabetes or for weight loss.
- Have received your initial prescription for semaglutide treatment.
- Have at least six months of follow-up since starting semaglutide treatment.
- Are willing and able to provide informed consent for study participation.
- Are able to complete the survey in English.

For more information or to participate, scan the QR code or:

- visit **[www.bccfe.ca/research/SALSA](http://www.bccfe.ca/research/SALSA)**
- call us at **(604) 806-8477 ext. 66272**



Semaglutide (Ozempic<sup>®</sup>, Wegovy<sup>®</sup>, and Rybelsus<sup>®</sup>) and Alcohol: a Self-reported Assessment (SALSA) Study  
in two Clinical Populations in Vancouver, British Columbia, Canada



BRITISH COLUMBIA  
CENTRE for EXCELLENCE  
in HIV/AIDS



Providence  
Health Care



SFU

REB Number - H25-00654  
PI: Dr. Julio Montaner  
Dr. Gregory Bondy

Version 1.1 - June 5, 2025